These results were also achieved with treatment of GBM cells with MELK inhibitor, OTSSP167, which significantly diminished MELK substrates, debrin-like (DBNL), and proteasome alpha subunit 1 (PSMA1) (41). This evidence concerns the gene PSMA1 and glioblastoma.